Here's why a leading fund manager is excited by this ASX healthcare share

WAM thinks this stock is capable of producing good returns.

| More on:
Two happy pharmacists standing together in a pharmacy.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investment outfit Wilson Asset Management (WAM) is always on the hunt for undervalued growth shares. Which might be why ASX healthcare share Sigma Healthcare Ltd (ASX: SIG) is a pick inside one of WAM's listed investment companies (LICs).

A LIC invests in shares/assets that it believes can produce good returns for shareholders, and WAM Research Limited (ASX: WAX) has a deep research process to find such opportunities. It looks at factors like free cash flowreturn on equity (ROE), meeting management, and a company's overall quality.

On paper, Sigma may not sound like a rapidly growing business. It describes itself as a leading Australian full-line wholesale and distribution business to pharmacies. It has retail pharmacy brands, including Amcal and Discount Drug Stores, as well as an independent offering called PriceSave.

But there's one key reason why WAM likes the ASX healthcare shares so much.

Potential merger with Chemist Warehouse

Sigma is currently attempting to merge with Chemist Warehouse, the biggest pharmacy business in Australia.

Combining the two companies would lead to significant scale, adding revenue and cost synergies. A combined business would have the potential to generate much bigger profits than if the two companies stayed separate.

The Australian Competition and Consumer Commission (ACCC) is considering this proposed merger carefully because it could reduce competition in the pharmacy space.

The ACCC said it had concerns, including "the potential harm to pharmacies currently supplied by Sigma and the potential for Chemist Warehouse to access these pharmacies' data in ways that damage competition".

However, Sigma recently offered a number of court-enforceable undertakings to attempt to allay the ACCC's fears.

WAM noted that despite the ongoing regulatory process, the market appeared more confident that the proposed merger with Chemist Warehouse would be approved.

The investment team said the Chemist Warehouse management remained confident in its ability to expand in Australia and overseas.

If the merger does get the go-ahead, the WAM team is "excited at the prospect of owning one of the country's best retailers with a global store roll-out on the horizon".

What will the ASX healthcare share do to get the deal across the line?

Sigma's undertakings include not preventing or hindering franchisees who entered into their franchising arrangements before 1 January 2024 from terminating their franchise agreements with Sigma for a period of three years.

Next, it would place restrictions on the collection, use and disclosure of confidential data and information from Sigma's wholesale customers and customers for a period of three years.

Finally, Sigma would also remain a participating pharmaceutical wholesale under the Commonwealth Government's Community Service Obligation (CSO) arrangements for at least five years.

The ACCC is seeking feedback about these moves to address competition concerns, and it continues to investigate the impact of the proposed acquisition.

Sigma Healthcare share price snapshot

The company's stock has climbed a hefty 85% since the start of 2024, as shown in the chart below.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

Has the Pro Medicus share price risen too high too quickly?

Pro Medicus shares have rocketed 173% since this time last year.

Read more »